Aprepitant Oral Powder for Suspension — FDA Drug Shortage

To Be Discontinued — Merck Sharp & Dohme LLC

The FDA lists a drug shortage record for Aprepitant Oral Powder for Suspension from Merck Sharp & Dohme LLC with status To Be Discontinued. The shortage was first posted on Apr 8, 2026.

Shortage details

Status
To Be Discontinued
Company
Merck Sharp & Dohme LLC
Package NDC
0006-3066-03
Presentation
Emend, Oral Powder for Suspension, 125 mg (NDC 0006-3066-03)
Initial Posting
Apr 8, 2026

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.